Droby, Amgad http://orcid.org/0000-0002-6182-0059
Artzi, Moran
Lerman, Hedva
Hutchison, R. Matthew
Bashat, Dafna Ben
Omer, Nurit
Gurevich, Tanya
Orr-Urtreger, Avi
Cohen, Batsheva
Cedarbaum, Jesse M.
Sapir, Einat Even
Giladi, Nir
Mirelman, Anat
Thaler, Avner
Funding for this research was provided by:
This study was funded by Biogen Inc.
Article History
Received: 22 July 2021
Accepted: 1 February 2022
First Online: 3 March 2022
Competing interests
: A.D., M.A., H.L., D.B.B., N.O., A.O.U., B.C., E.E.S. report no competing interests. T. Gurevich reports no competing interests relevant to this work. She received advisory board membership with honoraria to her and her institution from Abbvie Israel, Neuroderm Ltd. and Allergan. She recieves research support from Phonetica Ltd., Israeli Innovation Authority, Sagol School of Neuroscience (Brain Boost), and Parkinson’s Foundation. She received travel support from Abbvie, Allergan, Medisson, and Medtronic. RM. Huchison is an employee of and owns stock in Biogen. J.M. Cedarbaum is a former employee of Biogen, and reports no competing interests relevant to this work. N. Giladi has no competing interests pertaining to this work. He serves as a member of the editorial board for the Journal of Parkinson’s Disease. He serves as consultant to Sionara, Accelmed, Teva, NeuroDerm, Intec Pharma, Pharma2B, Denali and Abbvie. He received royalties from Lysosomal Therapeutics (LTI) and payment for lectures at Teva, UCB, Abbvie, Sanofi-Genzyme, Bial, and Movement Disorder Society. He received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program, and the Israel Science Foundation as well as from Teva NNE program, Biogen, LTI, and Pfizer. A. Mirelman reports no competing interests relevant to this work. She reports serving as advisor to Neuroderm. A. Thaler reports receiving honoraria from Abbvie- Israel. He reports no competing interests relevant to this work.